Table 3.

Cytogenetics of multiple myeloma patients with secondary MDS/AML

Secondary diagnosis	ISS stage diagnosis	Time until relapse on Lenalidomide (months)	Cytogenetics	Deletions FISH	Additions (known)‐FISH	Additions (unknown)–FISH	Translocations– FISH
MDS/RAEB‐2	3	22.8	44~47, XY 46, XY[4]	−4, del (4) (q12), del(4) (q21)), −17, −18, −21	add (7) (q22), add (11) (q23), add (14) (q32)	+mar1, +mar2, +mar3, +mar4 [cp15]
MDS/Plasma cell leukemia	2	30.1	45, XY 46, XY[2]	−13	–	+mar [cp2]	der (19) (p13.3;?) [16] der (19) r (19;?)
MDS	2	8.4	46 XY (normal)	Unknown	Unknown	Unknown	Unknown
MDS/SCC	Unknown	23.0	46, XX	−5, del (6) (p21.3[2]	add (17) (p11.2) add (17) (D5S721‐, D5S23−, EGR1+) (TP53−, D17Z1+)	+mar [6]	–
AML	1	64.0	43~45, XX	−5, del(7;17)(p10;q10) −14, −18	add (12)(p11.2),del(12)(p11.2p13) add (14)(p11.2)add (18)(q23), −20, i(21)(q10),add (22)(p11.2), add (22) (p13), +1~3r[cp12]	–	–
MDS	2	34.7	Unknown	5q−, −18	–	–	–

SPM, secondary primary malignancies; Dx, diagnosis; MDS, myelodysplastic syndrome; SCC, squamous cell carcinoma; ASCT, autologous stem cell transplant; FISH, fluorescent in situ hybridization; RAEB, refractory anemia with excess of blasts.